ETANERCEPT ON STEROID-REFRACTARY ACUTE GRAFT-VERSUS-HOST DISEASE
Servicio de Farmacia, 1Servicio de Hematología. Hospital Universitario de Gran Canaria, Dr. Negrín Las Palmas de Gran Canaria, Gran Canaria, Spain

OBJECTIVES

Allogeneic hematopoietic stem cell transplantation (HSCT) is the first-line treatment for many hematologic diseases. The graft-versus-host disease (GVHD) is the major complication of HSCT.

Steroids are the mainstay treatment of GVHD for decreasing the systemic pro-inflammatory response. In about a half of patients, steroid treatment fails and they have to be treated with other immunosuppressive drugs. Among them, therapy with anti-TNF drugs like etanercept is becoming an option for digestive manifestations of GVHD.

To describe etanercept use and effectiveness on steroid-refractory acute graft-versus-host disease, after hematopoietic cell transplantation

METHODS

Patients treated with Etanercept, as off-label use for steroid-refractory acute graft-versus-host disease, were selected and each patient’s medical history was reviewed to assess the clinical response.

RESULTS AND DISCUSSION

The study included 5 patients: 4 presented with digestive manifestations and one 1 presented pulmonary and liver manifestations. 4 patients showed a clinical response: 3 of them a partial response and 1 a total response.

In 4 cases, etanercept 25mg was administered twice a week with variable duration of treatment, achieving no response in 1 case (3 weeks), partial response in two 2 cases (4 weeks and 8 weeks) and a complete response in 1 case (8 week period). Only one 1 case was treated with etanercept 50mg administered twice a week for 5 weeks with a partial treatment response.

CONCLUSIONS

Previously published data estimates the response rates at about 60-62%, which is consistent with our results. This updates the scarce bibliographic information about etanercept use in steroid-refractory acute graft-versus-host disease. Due to clinical design limitations and the small patient population, future clinical studies should be conducted to assess the efficacy and safety of etanercept in these patients.